Breaking News, Financial News

Financial Report: Charles River Labs

Preclinical segment sales up 5% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Labs   1Q Revenues: $299.4 million (+3%) 1Q Earnings: $32.4 million (+26%) Comments: RMS segment sales were $185.6 million in the quarter, up 2%, with growth in the Endotoxin and Microbial Detection (EMD) business. Preclinical Services (PCS) segment sales were $113.8 million, up 5% driven by continued demand from mid-tier biotechnology clients....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters